Interferon beta / IFN-beta / IFNB Protein

• Description:

  Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS) . Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.

• Synonyms:

  IFB Protein; IFF Protein; IFN-beta Protein; IFNB Protein

• Accession Number:

  P01574

• Reactivity:

  Human

• Cross Reactivity:

  Human

• Assay Protocol:

  See Datasheet send with the product

• Endotoxin:

  < 1.0 EU per μg protein as determined by the LAL method.

• Purity:

  > 95 % as determined by SDS-PAGE.

• Bioactivity:

  Measured in antiviral assays using WISH cells infected with vesicular stomatitis virus. The ED50 for this effect is typically 0.2-3pg/mL.

• Length:

  166

• Form:

  Lyophilized or frozen liquid

• Buffer:

  0.2 μm filtered acetate buffer solution

• Reconstitution:

  See Datasheet

• Molecular Weight:

  23 kDa (glycosylated)

• Storage Conditions:

  Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

• Host or Source:

  CHO cells